登录

CytoNiche Snags ¥10M in Series A Funding Round

作者: Mailman 2020-09-07 17:06
华龛生物
http://www.cytoniche.com/
企业数据由 动脉橙 提供支持
3D细胞技术产品与服务提供商 | B轮 | 运营中
中国-北京
2022-03-03
融资金额:RMB¥3亿
高榕资本
查看

According to VCBeat, CytoNiche Biotechnology ("CytoNiche") recently announced the completion of a Series A financing of tens of millions, with participation from Beijing Shoufazhan Tianji Fund, Detong Capital and an international industrial group. Haoyue Capital acted as the sole financial advisor for the latest round.


CytoNiche focuses on the research and development of 3D micro-tissue engineering technology. The core technology comes from the project conducted by Tsinghua University. Based on its original research technology, CytoNiche has launched a series of products and services, including customized, large-scale, automatic and intelligent stem cell culture and amplification process, 3D stem cell microtissue regeneration therapies and 3D cell high-throughput drug screening products.


CytoNiche now has a 1000m2 R&D center and a 2000m2 GMP production base. The company has obtained over 30 patents and published more than 30 articles in well-known international journals such as Nature Materials, PNAS, Nature Communication, Biomaterials, and have been widely reported at home and abroad.


3D FloTrix® series products developed by CytoNiche are an original overall solution that can realize the large-scale culture and amplification of stem cells, as well as an innovation in pharmaceutical injection for stem cells.


The three-dimensional culture system of CytoNiche's stem cells can solve many problems such as low efficiency of traditional two-dimensional amplification culture of stem cells, difficulties in continuous cultivation, inability to efficiently expand, unstable quality of stem cell products and so on.


CytoNiche's products have achieved mass production in the GMP system and stable sales. Its core products are in the stage of clinical application. The company has signed strategic cooperation agreements with a number of firms of  IND applications and new drug applications to jointly promote the development of new drugs in cellular therapy.


>>>>

About Detong Capital 


Detong Capital is a private equity investment firm that provides growth capital to early and expansion-stage companies. It invests in dynamic businesses that have high growth potential, strong management teams, and demonstrated revenue models in both technology-based and traditional industries.

相关赛道 IVD
注:文中如果涉及企业数据,均由受访者向分析师提供并确认。
声明:动脉网所刊载内容之知识产权为动脉网及相关权利人专属所有或持有。转载请联系tg@vcbeat.net。

Mailman

医疗行业观察者

分享
动脉橙
以上数据来自动脉橙产业智库

我们以独创的在线数据库方式,为健康产业人士提供全方位和实时的市场资讯、行业数据和分析师见解。现已覆盖数字健康、医疗器械、生物医药等近500+细分赛道,涉及公司名单、招投标、投融资信息、头部企业动态等各类数据并持续更新。

点击 【申请试用】了解动脉橙产业智库更多内容。
精彩内容推荐

【首发】科进生物完成近亿元融资,助力解决细胞培养新材料的“卡脖子”问题

【首发】占据基因编辑技术制高点,齐禾生科完成逾亿元人民币种子轮融资

【首发】裕策生物完成近亿元C+轮融资,全力打造肿瘤免疫诊疗整体解决平台

【首发】深圳汇芯生物完成千万级天使轮融资,凯风创投独家投资

Mailman

共发表文章3245篇

最近内容
  • 知之甚少:调研885名投资人后,原来美国VC们这样做决策

    2023-03-20

  • 辉瑞想要收购Seagen只是开始,这才是2023年并购的两大趋势

    2023-03-05

  • 【融资】核药企业Ratio再融资2000万美元,和拜耳合作研究新前列腺癌放射性疗法

    2023-02-09

上一篇

InxMed Closes ¥130M Series A+ Round of Financing

2020-09-07
下一篇

TongliBio Raises ¥10M in A New Round of Financing

2020-09-07